1 / 58

Novel Strategies for the Treatment of AML: Tailoring Treatment For Specific Genetic Subtypes

Novel Strategies for the Treatment of AML: Tailoring Treatment For Specific Genetic Subtypes. Martin S. Tallman, M.D. Northwestern University Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Chicago, IL. Topics To Address. Introduction and epidemiology

jola
Download Presentation

Novel Strategies for the Treatment of AML: Tailoring Treatment For Specific Genetic Subtypes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Strategies for the Treatment of AML: Tailoring Treatment For Specific Genetic Subtypes Martin S. Tallman, M.D. Northwestern University Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Chicago, IL

  2. Topics To Address • Introduction and epidemiology • Overview of current therapy • Distinguishing genetic subtypes • Novel strategies for specific genetic subtypes • Future Directions

  3. Introduction • New patients/deaths in 2004: 12,000/9,000 • Median age of AML: 68 years • Heterogeneity in genetics and clinical manifestations • Outcome varies by prognostic factors

  4. Epidemiology • Therapy-related (alkylating agent or topo II active agents) • Evolving from MDS or MPD • Congenital chromosomal instability syndromes • Higher frequency of APL in Latin Americans1 • Higher frequency of t(8;21) in Japan2 1Douer Blood, 1996, Br J Haematol, 2003; 2Nakase Leukemia, 2000

  5. Current Treatment Results In Younger Adults

  6. Current Treatment Results In Older Adults

  7. Prognostic Factors • Age • Intensity of postremission therapy (younger adults) • Cytogenetics (distinguish fav- intermed- and unfav-risk groups)

  8. Estimate At Risk Deaths at 5 Years Favorable 121 53 55% Intermediate 278 168 38% Unfavorable 184 162 11% Overall Survival by Cytogenetic Group 100 80 60 Cumulative Percent 40 20 Heterogeneity of 3 Groups: p<.0001 0 0 2 4 6 8 Years After Entering Study Slovak Blood, 2000

  9. Prognostic FactorsMolecular Markers • Transmembrane transporter proteins which confer multidrug resistance (MDR1) • Mutations in or overexpression of specific genes-unfav. prognosis: WT1, BAX, BCL-2/BAX, BAALC, EVI1, KIT, FLT3, MLL,ERG;fav. prognosis: C/EBP, NMP1 Expressed in cells from pts with normal karyotype

  10. Outcome For AML with Fav-risk Cytogenetics 1Castaigne Blood, 2002; 2Appelbaum Proc ASCO, 2005; 3Marcucci J Clin Oncol, 2005; 4Sanz Pro ASCO, 2005; 5Lo Coco Blood, 2004

  11. Outcome For AML in Older Adults with Unfavorable Cytogenetics 1Grimwade Blood, 2004; 2Rowe Blood, 2004

  12. Current Therapeutic Strategies • Induction with anthracycline 45-60 mg/m2/day for 3 days + cytarabine 100 mg/m2/day for 7 days c.i. • Multiple cycles of high-dose ara-C consolidation • No maintenance (except APL)

  13. Strategies To Improve Outcome • Dose intensification (anthracyclines) • Alternative chemotherapy • Priming with growth factors • New agents

  14. Daunorubicin Dose Intensification 1Appelbaum Ann Int Med, 1984; 2Castaigne Blood, 2003; 3Kolitz Blood, 1998

  15. ECOG Priming StudiesRecruiting Leukemic Cells into Cell Cycle Rowe Blood, 2004

  16. Priming With Growth Factor (GF) in Younger Patients with Intermediate Cytogenetics 1Lowenberg NEJM, 2003; 2Thomas Blood, 2005

  17. Specific Genetic Subtypes of AML To Which Therapy Can Be Tailored • APL • CBF AML • CD33 pos AML • AML with FLT3 mutatations • AML with c-kit mutations • AML with MLL PTD

  18. Curative Strategies in APL Induction: ATRA + anthracycline-based chemotherapy Consolidation: Anthracycline-based chemotherapy for 2-3 cycles to molecular negativity Intermediate-dose ara-C for high-risk Maintenance: ATRA +/- low-dose chemo for 1-2 years; ? Role in PCR neg after consol Mol. Monitoring: RT-PCR from PB every 3-6 months for 2-3 years, prob for high-risk only Relapse: Arsenic followed by ASCT (allo if PCR pos) (consider prophylactic IT therapy)

  19. GIMEMA AIDA 2000 Overall Survival 1.0 .75 N=338 3 years: 87% Survival .50 .25 0 0 .5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 Years Courtesy of F. Lo Coco

  20. Advances in Therapy in APLParadigm for tailoring therapy to specific genetic subtype Will chemotherapy be eliminated?

  21. Arsenic Trioxide for Rel/Ref APL Pilot and US Multicenter Trial Overall and Relapse-Free Survival 100 80 60 Probability (%) 40 OS - 1st Relapse OS - > 1st Relapse 20 RFS - 1st Relapse RFS - > 1st Relapse 0 0 1 2 3 4 Years Soignet J Clin Oncol, 2001; Douer, Tallman J Clin Oncol, 2005

  22. Induction/ maintenance therapy N (%) CR Time to CR (days)  PML/RARα (fold) Relapse (%) (median follow-up 18 months) ATRA 20 95 40  10 6.7 26.3 ATO 20 90 35  3 32 11.1 ATRA + ATO 21 95 25  5 119 0 P — NS < .05 < .01 < .02* Randomized Trial of Arsenic Trioxide and ATRA in Untreated APL *All patients also treated with consolidation chemotherapy and 6-MP + MTX as maintenance Shen Proc Natl Acad Sci,U S A, 2004

  23. Disease-Free Survival by Treatment Group 1.0 0.8 0.6 Probability 0.4 ATRA + arsenic trioxide (n = 20) 0.2 arsenic trioxide (n = 18) ATRA (n = 19) 0 0 4 8 12 16 20 24 28 32 Time of Follow-up (months) Shen PNAS, 2004

  24. Induction With Single-Agent Arsenic Trioxide: Untreated APL Study N CR (%) PCR neg (%) Postremission therapy Zhang – China1 124 88 NR Chemotherapy Ghavamzadeh – Iran2,3,4 111 86 92 ATO  1 Chandy – India5,6,7 51 95 ATO  6 80 4Ghavamzadeh Ann Oncol, 2005 5George Haematologica, 2004 6George European Hematol Assoc, 2004 7Mathews Blood, 2005 (abstr) 1Zhang J Biol Regul Homeost Agents, 1999 2Ghavamzadeh ASCO, 2003[abst] 3Ghavamzadeh EHA, 2004[abst]

  25. North American Intergroup Trial C9710 Induction Consol #2 Maint Consol #1 ATRA6-MP MTX ATRA DaunoAra-C ATO ATRADauno UntreatedAPL CR No ATO ATRA7 days, QOW Tests arsenic as early consolidation and 2 maint regimens

  26. Proposed North American Intergroup Study-Phase IIILow- and Intermediate-Risk Induction Consol #1 Consol #2 Maint ATRA6-MP MTX neg ATRA DaunorubicinAra-C ATRADaunorubicin PCR OBS ATO pos GemtuzumabOzogamicin HSCT Tests benefit of maint in PCR neg patients

  27. Proposed North American Intergroup Study-Phase II High-Risk Induction Consol #1 Consol #2 Consol #3 Maint GemtuzumabOzogamicin ATRA6-MP MTX ATRAATOGemtuzumabOzogamicin ATRADaunorubicin ATO Tests benefits of 3 nonchemotherapy agents in induction

  28. Incidence of CBF AML by Age Appelbaum FR, Kopecky KJ, Tallman MS, et al (submitted)

  29. Outcome of t(8;21) AML Palmeri Leuk Res, 2002; Nishii Leukemia, 2003; Baer Blood, 1997; Marcucci J Clin Oncol, 2005; Appelbaum (submitted); Schlenk J Clin Oncol, 2004

  30. Outcome of inv16/t(16;16) AML Marcucci J Clin Oncol, 2005; Delaunay Blood 2003; Appelbaum (submitted); Schlenk J Clin Oncol 2004

  31. 100 5Year N Events Estimate inv 16 196 97 50% t(8;21) 174 100 45% 80 60 Percent 40 20 0 0 5 10 15 20 25 Years Outcome for CBF Leukemias 100 Overall Survival 80 5Year N Deaths Estimate All Patients 370 197 48% 60 Percent 40 20 0 0 5 10 15 20 25 Years Overall Survival by Abnormality Disease-Free Survival by Treatement 5Year N Events Estimate FA 53 20 61% HCT 31 12 61% HDAC 44 23 50% Other 136 96 31% 100 80 60 Percent 40 20 0 0 5 10 15 20 25 Years After Start of Post-CR Regimen Appelbaum et al.(submitted)

  32. CALGB Protocol 19808: Induction +/- MDR Modulation Followed by Cytogenetic Risk-Adapted Intensification in Younger Adults HiDAC Consolidation Therapy x 3 Favorable Cytogenetics ADE Obs. HiDAC G-CSF VP-16 If able to Receive PSCT BU/VP-16 PSCT Stem Cell Mobilize IL-2 Unfavorable Cytogenetics If unable to Receive PSCT HiDAC Consolidation Therapy x 2 ADEP VP-16 HiDAC G-CSF Tests HiDAC for fav. Cyto and IL-2 post-ASCT

  33. Specific Genetic Subtypes Are Heterogeneous: t(8;21) • CD56 expression may confer poor prognosis • Associated trisomy 4 is a distinct subtype with poor prognosis • Receptor tyrosine kinase pathway mutations in 49% and confer poor prognosis Baer Blood, 1997; Nishii Leukemia 2003; Nanri Leukemia 2005

  34. New Agents

  35. O O O Me Me O HO NHN S NH Me O CH S O 3 CH 3 I O OCH 3 S O CH 3 O H HN O OCH OH O 3 HO OCH O O CH 3 3 Et HO O OCH 3 N OH CH 3 OCH 3 O Gemtuzumab Ozogamicin • Structure • hP67.6 - humanized anti-CD33 antibody • Blue- linker • Periwinkle - calicheamicin hP67.6 HN • Approved for adults > 60 in first relapse • Induces CR + CRp in ~ 30%1,2 • Rare VOD/SOS if allo < 3.5 mo.3 1Sievers J Clin Oncol, 2001; 2Larson Leukemia, 2002; 3Wadleigh Blood, 2003

  36. Gemtuzumab Ozogamicin 1Estey Blood, 2002; 2Nabhan Leukemia Res, 2004; 3Amadori Blood, 2004 [abstr]

  37. Gemtuzumab Ozogamicin in Induction Prompts SWOG Phase III trial of chemotherapy +/- GO d4 DeAngelo Blood, 2003 (abstr); Kell Blood, 2003

  38. ECOG ProtocolE1900: Dose Intensification in Induction and Gemtuzumab Ozogamicin (GO) pre-ASCT in Younger Adults with Untreated AML Daunorubicin45 mg/m2/day + Cytarabine High Risk Allogeneic HSCT CR Autologous ASCT HiDAC x 2 PBSH after 2nd course Daunorubicin90 mg/m2/day + Cytarabine GO 6 mg/m2 IV day 1 Tests anthracycline dose intens and GO as in vitro purge pre- ASCT

  39. Inhibition of Multidrug Resistance • P-gp-mediated MDR plays major role in clinical resistance to chemotherapy • P-gp correlates inversely with CR • 71% of patients > age 60 express moderate to high P-gp1 • Major limitation is alteration in pK of concomitant chemotherapy 1Leith Blood, 1994

  40. MDR Modulation Studies in AMLDe novo > 60 years 1Baer Blood, 1999; 2 Van der Holt Blood, 2004 (abstr)

  41. Inhibition of Multidrug Resistance LY335979 (Zosuquidar) • Selective P-gp inhibitor with high affinity1 • In vitro conc of 50-100nM circumvent P-gp-mediated resistance 2,3 • Does not alter PKs of co-administered drugs2 • Phase II trial in poor-risk AML CR or mCR 42%4 • ECOG phase III trial 1Sato Cancer Res, 1991; 2Dantzig Cancer Res, 1996; 3Green Biochem Pharmacol, 2001; 4Cripe Blood, 2001 (abstr)

  42. V A L U A T E ECOG Protocol E3999: Dauno + Cytarabine +/- Zosuquidar in Older Adults Induction Consolidation I Daunorubicin Cytarabine Zosuquidar E Cytarabine CR or MR Consolidation II Daunorubicin Cytarabine Placebo Daunorubicin Cytarabine Placebo Daunorubicin Cytarabine Zosuquidar Tests novel MDR modulator

  43. Ras • Ras mutations • Activating mutations in 10-30% of AML1,2 • Frequent in t(3;5) and inv(16)3 • Active inhibition of farnesyl transferase (FT), inhibits ras protein • Inhibitors of FT active in AML4,5 • Gene expression profiling may predict response to Tipifarnib6 1Radich Blood, 1990; 2Neubauer Blood, 1999; 3Bowen Blood, 2005; 4Karp Blood, 2001; 5Lancet Blood, 2002; 6Raponi Blood, 2005

  44. Tipifarnib-Phase II Trial in Untreated High-risk AML/MDS • Med age 74 yrs (46-85) • CR in 21% • Med CR dur 5-8 mo. (1.5-11+) • Gr. 4 neutropenia 13% • Inhibition of FT in 74% of samples • Encouraged US Intergr Phase II trial of 2 different doses/schedules in older adults Lancet Blood, 2003 (abstr)

  45. S0432: US Intergroup Phase II StudyZarnestra for Previously Untreated AML in Patients > Age 70

  46. AML With Mutant RAS and Cytarabine Intensification Neubauer ASCO, 2005

  47. Prognostic Significance of FLT3 ITD 100 80 60 Survival (%) ITD- n=627 44% 40 ITD+ n=227 32% 20 P<0.001 0 0 3 1 4 2 5 Years Kottaridis Blood, 2001

  48. Tyrosine Kinase Inhibitors PKC412 • Staurosporine-derived, targets PKC, KDR, VEGF-R2, PDGFR, c-KIT, FLT3 • Phase II study1 – 28 pts with FLT3 mutation, HI in 50%, but no CR or PR CEP-701 • Indolcarbazole alkyloid-targets TrkA, VEGFR, FLT3 • Phase I/II study2-14 pts with FLT3 mutation, biologic activity in 35%, but no CR or PR 1Estey Blood, 2003; Smith Blood, 2004

  49. FLT3 Inhibitors and Chemotherapy in AML • CEP-7011 • N=34 in first relapse • MEC or HiDAC +/- CEP-701 • 10/17 CR with CEP-701 • PKC4122 • N=19 de novo • Dauno + Ara-C + PKC412 • CR 71-75% • 100% FLT3 mut • 62% FLT3 wt 1Lewis, Blood, 2005 (abstr); 2Stone, Blood, 2005 (abstr)

  50. FLT3 Inhibitors • In vitro data strong • Modest clinical activity-few, if any, CRs • How best to develop? • Focus on combinations with chemotherapy1, 2; Phase III US Intergroup trial planned (dauno + ara-C +/- PKC412) • Will combining agents with in vitro activity, but modest clinical activity, be effective? • 1Stone Blood, 2005; Levis, Blood 2005

More Related